ChromaDex Corp. (CDXC)

[Milarepa]

Probably nothing. The important litigation now is before the Patent Trial and Appeal Board (should be resolved this month), and in federal court in California (trial in July) and Delaware (just getting started). ChromaDex is asserting claims for patent infringement and trade secret theft that could result in significant damage awards. Elysium will be trying to invalidate or otherwise evade ChromaDex's patents, either of which could have a big impact depending on who wins.

The FDA matter is now gone, and the remaining false advertising and unfair business practices claims in New York seem relatively unimportant, but I might change my mind depending on what develops there.

In sum: If either side wins on the big claims, or if investors think that the litigation is going to go away entirely, that would be more likely to influence the share price.

Stay tuned for the PTAB determination later this month (if not delayed by the government closure). If Elysium loses there, again, too, then people might start to conclude that their claims are specious and the litigation is not likely to go their way.

For more info, visit:
https://www.right-of-assembly.org/litigation